StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) stock

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.19+0.00 (+2.01%)

Close on Nov 17, 2026Market cap $8.34MP/E –Yield –

Vistagen Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Vistagen Therapeutics's price to sales ratio was 3.1× on Nov 11, 2026, against 98.3× a year earlier. Over the last 5 years it ranged from 2.7× to 331.1×, with a median of 78.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.1×−99.6
2025Apr 30, 2025102.6×+0.5
2024Dec 31, 2024102.1×+52.3
2023Dec 29, 202349.8×+25.1
2022Oct 31, 202224.7×−178.0
2021Dec 31, 2021202.7×−100.3
2020Dec 31, 2020303.0×+290.7
2017Jul 31, 201712.4×−51.1
2013Jul 31, 201363.4×+45.4
2012Dec 31, 201218.1×−7.6
2011Dec 30, 201125.7×–

More Vistagen Therapeutics figures

See a number that looks wrong?